The Excellent CAR-T Clinical Trial Saves Hong Kong B-ALL Patient
Shawn, 29-years-old man comes from Hong Kong. In March 2017, has symptoms of fever, fatigue and pale. In Prince of Wales Hospital was diagnosed as acute B lymphocytic leukemia and got one course of induction chemotherapy. In April, he got complete remission by Chemotherapy and radiotherapy. And no abnormalities were found in cerebrospinal fluid correlation report.
However, until 19thApril 2018, his bone marrow morphology showed 10% of primary and juvenile gonorrhea. Hong Kong doctors think chemotherapy is hard to make him into complete remission，only CAR-T have a big chance to make it. After the doctors’ recommendation and compared the successful rate and expenditure Shawn came to Lu Daopei hospital China for taking part in the CAR-T clinical trial in April 23 2018.
Admission bone marrow biopsy test showed he was not in complete remission and the CD19、CD20 are positive. After multi-discipline consultation meeting, our hematologists suggest him to take part in the CD19+CD20 CAR-T clinical trial before bone marrow transplantation. In our 300 cases of CAR-T, the complete remission rate is about 90%.
On April 25th, T-cells were collected from Shawn and delivered to the GMP level CAR-T lab for genetically engineered. After the genetically engineered, the T-cells were transformed to “chimeric antigen receptor (CAR) T cells.” CARs are proteins that strengthen the T cells to recognize an antigen on targeted tumor cells. After cultured the CAR-T cells to enough treatment quantity, CAR-T cells will be infusion to him to eliminate tumor cells.
Shawn got 1 course of chemotherapy on May 6th which is 5 days before infusion of CAR-T cells. On May. 11thCD19-CART cells infusion was done as cellular immune therapy. After 4 weeks of supportive care and side effect management, no abnormalities were found in cerebrospinal fluid correlation report, flow cytometry, marrow cell morphology, DNA test and CAR-T report showed that he got complete remission.
The complete remission condition lays the best foundation for him to go back to Hong Kong to take the next step-Blood and Bone Marrow Transplantation.